Sign In
Buy DMTK
$0.0940
+0 (+0%)
At Close: Oct 21, 2024
DermTech: Transforming The Melanoma Diagnosis Landscape
10:31am, Tuesday, 31'st Aug 2021
DermTech: Transforming The Melanoma Diagnosis Landscape
Got $100? 3 Smart Growth Stocks to Buy Right Now
05:55am, Monday, 30'th Aug 2021
A C-note will allow you to pick up shares of all three of these great stocks.
DermTech: Becoming More Appealing, Despite Nosebleed Valuation
08:36pm, Sunday, 08'th Aug 2021
DermTech reported Q2 2021 earning recently, on August 4, 2021. In the quarter, Dermtech beat both internal and analyst revenue estimates, but they missed analyst earnings by $0.06.
DermTech, Inc. (DMTK) CEO John Dobak on Q2 2021 Results - Earnings Call Transcript
11:13pm, Wednesday, 04'th Aug 2021
DermTech, Inc. (DMTK) CEO John Dobak on Q2 2021 Results - Earnings Call Transcript
DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates
07:04pm, Wednesday, 04'th Aug 2021
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 11.11% and 11.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: DermTech Q2 Earnings
05:03pm, Wednesday, 04'th Aug 2021
Shares of DermTech (NASDAQ:DMTK) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 1.72% over the past year to ($0.59), which missed the es
DermTech to Announce Second Quarter Financial Results on August 4, 2021
04:30pm, Wednesday, 21'st Jul 2021
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to relea
3 Healthcare Stocks That Could Make You Rich
05:55am, Wednesday, 21'st Jul 2021
They're disruptors that could change healthcare.
This Medical Device Company Is Changing the Game in Skin Cancer
07:57am, Sunday, 18'th Jul 2021
And it's on sale right now.
DermTech CEO John Dobak, M.D. Wins San Diego Business Journal CEO of the Year Award, Public Company, Medium Category
05:00pm, Thursday, 24'th Jun 2021
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech CEO
DermTech to Partner with University of Barcelona for Research Study on Atopic Dermatitis and Psoriasis
04:30pm, Tuesday, 22'nd Jun 2021
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today a collaboration w
DermTech: Revolutionizing The Skin Cancer Diagnostics Market
10:56am, Tuesday, 22'nd Jun 2021
DermTech: Revolutionizing The Skin Cancer Diagnostics Market
DermTech: Disrupting Skin Cancer Testing
08:11am, Tuesday, 22'nd Jun 2021
DermTech: Disrupting Skin Cancer Testing
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today three new key lea
DermTech Announces Three New Scientific Advisory Board Members
04:30pm, Wednesday, 02'nd Jun 2021
LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the additions of
